Clinical Case Series - 26aml - Question 3

When treating patients with relapsed AML using therapies with differentiation-based mechanisms, how long do you typically continue treatment before determining lack of efficacy in the absence of disease progression?

Discontinue within 2–4 weeks if no hematologic improvement is observed

Continue for at least 6–8 weeks if there is evidence of biologic activity (e.g., blast reduction or differentiation)

Continue indefinitely regardless of response

Continue for up to 6 months to allow for delayed response, particularly if there are signs of clinical activity

Discontinue only after worsening cytopenias occur

Unsure

{"name":"Clinical Case Series - 26aml - Question 3", "url":"https://www.poll-maker.com/QH46XK3IC","txt":"When treating patients with relapsed AML using therapies with differentiation-based mechanisms, how long do you typically continue treatment before determining lack of efficacy in the absence of disease progression?","img":"https://www.poll-maker.com/3012/images/ogquiz.png"}

Tools: Poll Maker | Quiz Maker